NCCN Guidelines® Insights - Myelodysplastic Syndromes, Version 2.2015
The NCCN Guidelines for Myelodysplastic Syndromes (MDS) comprise a heterogeneous group of myeloid disorders with a highly variable disease course that depends largely on risk factors. Risk evaluation is therefore a critical component of decision-making in the treatment of MDS. The development of newer treatments and the refinement of current treatment modalities are designed to improve patient outcomes and reduce side effects. These NCCN Guidelines Insights focus on the recent updates to the guidelines, which include the incorporation of a revised prognostic scoring system, addition of molecular abnormalities associated with MDS, and refinement of treatment options involving a discussion of cost of care.
This activity has been designated to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to the NCCN Guidelines for Myelodysplastic Syndromes
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Myelodysplastic Syndromes
- 1.00 Participation
- 1.00 Nurse
- 1.00 Pharmacist
- 1.00 Physician